BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jayasundera KT, Abuzaitoun RO, Lacy GD, Abalem MF, Saltzman GM, Ciulla TA, Johnson MW. Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases. Am J Ophthalmol 2022;235:90-7. [PMID: 34433085 DOI: 10.1016/j.ajo.2021.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li ZF, Wu NQ. The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy. Front Genet 2022;13:911429. [PMID: 35754818 DOI: 10.3389/fgene.2022.911429] [Reference Citation Analysis]
2 Selvan K, Abalem MF, Lacy GD, Vincent A, Héon E. The State of Patient-Reported Outcome Measures for Pediatric Patients with Inherited Retinal Disease. Ophthalmol Ther. [DOI: 10.1007/s40123-022-00514-x] [Reference Citation Analysis]
3 Novack G. Expedited regulatory product approval in the time of COVID-19. The Ocular Surface 2022. [DOI: 10.1016/j.jtos.2022.05.007] [Reference Citation Analysis]
4 Kalatzis V, Roux AF, Meunier I. Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date. Mol Diagn Ther 2021. [PMID: 34661884 DOI: 10.1007/s40291-021-00558-y] [Reference Citation Analysis]